Tag: KDC-MN-282

  • Triptorelin

    Synthetic GnRH agonist (decapeptide)

    A synthetic GnRH agonist decapeptide used for paradoxical HPG suppression in prostate cancer, endometriosis, and precocious puberty.

    Abstract

    Triptorelin (5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolylglycinamide; CAS 57773-63-4; molecular formula C64H82N18O13; molecular weight 1311.45) is a synthetic GnRH (LHRH) agonist decapeptide developed in the 1970s and approved by the FDA in 2000 (Trelstar). Mechanism: continuous occupation of pituitary GnRH receptors initially produces a flare in LH, FSH, and consequent sex hormone secretion (1 to 2 weeks); chronic exposure desensitizes and downregulates GnRH receptors, producing a sustained reduction in LH and FSH and, downstream, in testosterone (men) and estradiol (women). Plasma half-life of the parent peptide is approximately 3 hours; depot formulations release peptide over 1, 3, or 6 months for sustained suppression. Approved indications include locally advanced and metastatic prostate cancer, endometriosis, uterine leiomyomata, and central precocious puberty. The flare period in prostate cancer is mitigated by concurrent androgen receptor antagonist (bicalutamide). Used as a reference GnRH agonist in academic endocrine pharmacology.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.